TY - JOUR
T1 - Molecular mechanisms of enzalutamide resistance in prostate cancer
AU - Blatt, Eliot B.
AU - Raj, Ganesh V.
N1 - Funding Information:
This work was supported by the Department of Defense (W81XWH017-1-0674) and the Prostate Cancer Foundation (18CHAL16), as well as support from the Cole Foundation and the Wilson Foundation.
Publisher Copyright:
© The Author(s) 2019.
PY - 2019
Y1 - 2019
N2 - An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.
AB - An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.
KW - Biomarkers of drug responsiveness
KW - Drug resistant cancers
KW - Resistance modulation
KW - Targeted therapy resistance
UR - http://www.scopus.com/inward/record.url?scp=85083781741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083781741&partnerID=8YFLogxK
U2 - 10.20517/cdr.2019.25
DO - 10.20517/cdr.2019.25
M3 - Review article
C2 - 35582713
AN - SCOPUS:85083781741
SN - 2578-532X
VL - 2
SP - 189
EP - 197
JO - Cancer Drug Resistance
JF - Cancer Drug Resistance
IS - 2
ER -